<DOC>
	<DOCNO>NCT01788072</DOCNO>
	<brief_summary>There substantial evidence animal model healthy control data , oxytocin involved modulation social cognition . In addition , recent genetics plasma level study suggest possible role oxytocin pathophysiology Autism Spectrum Disorders ( ASD ) . As large number child ASD transition adulthood likely require treatment , lack data make meaningful treatment recommendation facilitate adult live urgent issue . This study examine effect intranasal oxytocin ( IN-OXT ) social function adult ASD . It hypothesize IN-OXT superior placebo improve social function end study treatment .</brief_summary>
	<brief_title>INtranasal OXyTocin Treatment Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female outpatient 1845 year age , inclusive 2 . Meet Diagnostic Statistical Manual Mental Disorders . Diagnostic Statistical Manual ( DSMV ) criterion establish clinician expertise individual ASD . Best estimate Diagnosis reach use DSMV criterion , Autism Diagnostic Observation Schedule ( ADOS ) Autism Diagnostic Interview ( ADIR ) . 3 . Have Clinical Global ImpressionSeverity ( CGIS ) score ≥ 4 ( moderately ill ) Screening . 4 . Verbal scale Intelligence Quotient ( IQ ) ≥ 70 5 . If already receive stable concomitant medication affect behavior , stable regimen change precede 1 month prior Screening ( exception fluoxetine , period 6 week need ) , electively initiate new modify ongoing medication duration study 6 . If already receive stable nonpharmacological educational , behavioral , and/or dietary intervention , continuous participation precede 3 month prior Screening , electively initiate new modify ongoing intervention duration study 7 . Have normal physical examination laboratory test result screen . If abnormal , find ( ) must deem clinically insignificant Treating Clinician . 8 . Ability speak understand English sufficiently allow completion study assessment 9 . Ability obtain write informed consent subject ( developmentally appropriate ) , ability obtain write informed consent surrogate decision maker ( SDM ) , subject unable provide consent . Exclusion Criteria 1 . Patients born prior 28 week gestational age 2 . Patients primary psychiatric diagnosis ASD 3 . Patients medical history neurological disease , include , limited , epilepsy/seizure disorder , movement disorder , tuberous sclerosis , fragile X , know genetic syndrome , know abnormal brain MRI/structural lesion . Exceptions : 1 ) simple febrile seizure , 2 ) epilepsy/ seizure free least 2 year prior Screening 4 . Pregnant female patient , sexually active female patient hormonal birth control sexually active female use least two type nonhormonal birth control 5 . Patients evidence history malignancy significant hematological , endocrine , cardiovascular ( include rhythm disorder ) , respiratory , renal , hepatic , gastrointestinal disease 6 . Patients one following : HIV , Hepatitis B virus , Hepatitis C virus , hemophilia ( bleed problem , recent nose brain injury ) , abnormal blood pressure ( hypotension hypertension ) , drug abuse , immunity disorder severe depression . 7 . Patients unable tolerate venipuncture procedure blood sample 8 . Patients currently take oxytocin take intranasal oxytocin past response 9 . Patients sensitivity oxytocin component formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Oxytocin</keyword>
	<keyword>Adults</keyword>
</DOC>